Pfizer, Haleon
Pfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
Pfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner
Pfizer intends to sell about 540 million shares in British consumer healthcare company Haleon , a bookrunner said on Monday, reducing the top shareholder's interest in the Sensodyne maker to 16.2%.
TOP NEWS: Pfizer to raise around GBP2.7 billion from Haleon stake sale
On completion, Pfizer, the New York-based pharmaceuticals firm, will see its interest in Haleon fall to just over 16% from 22.6% currently. Bloomberg reported that the share sale price is likely to be 380 pence per share, raising around GBP2.7 billion.
Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says
Sept 30 (Reuters) - Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon, a bookrunner said on Monday. The proposed sale will reduce the top shareholder's interest in Sensodyne-maker Haleon to 16.
GlobalCapital5h
Fireworks in ECM with Haleon block and NBG privatisation
Goldman Sachs, JP Morgan, Morgan Stanley and UBS are global coordinators on the trade, with Barclays, Bank of America, BNP ...
Pfizer Set to Raise £2.7 Billion From Haleon Stake Sale
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...
Dr Reddy's Laboratories completes acquisition of Haleon's NRT portfolio
Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global ...